{# ── Non-reliance notice. Reaching the live report with one of these means it did not meet the blocking bar (the 4.02 names this period outside the Item 4.02 body) or the viewer is staff. Either way the reader must not take the figures at face value. ── #}

Get notified when DNLI files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: DNLI Denali Therapeutics Inc. 8-K

Denali completes $195M sale of Priority Review Voucher from Hunter syndrome drug approval

Filed July 28, 2026 · Period ending July 27, 2026 · ~1 min read

Key Changes

  • high

    Denali received $195.0 million in gross proceeds from selling its Priority Review Voucher to a large pharmaceutical company, providing significant capital for operations and R&D.

    Item 2.01 verify on EDGAR →
  • medium

    The PRV was awarded when FDA approved AVLAYAH (tividenofusp alfa) for Hunter syndrome in March 2026; these vouchers expedite FDA review and are tradable assets.

    Item 2.01 verify on EDGAR →

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (IMMR 10-K) is open in full — no account needed.

Partner

Trade DNLI commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Source-verified from EDGAR · Narrative written by AI · Jul 29, 2026 · How we verify